Akeso Reports 28.7% Revenue Growth, Expands IO2.0 Strategy with Key Approvals
Event summary
- Akeso reported a 28.7% year-over-year increase in commercial sales revenue to RMB 1,803.2 million for H1 2026.
- NMPA approved ivonescimab in combination with chemotherapy for first-line treatment of advanced squamous NSCLC in August 2026.
- Phase III study of ivonescimab plus chemotherapy met primary endpoint of overall survival in biliary tract cancer.
- Cadonilimab advancing in multiple indications, including gastric cancer and hepatocellular carcinoma.
- Akeso's IO2.0 + ADC2.0 therapeutic matrix includes over 17 registrational Phase II/III studies for ivonescimab and 13 for cadonilimab.
The big picture
Akeso's strong commercialization momentum and strategic advancements in its IO2.0 global strategy position it as a key player in the immuno-oncology space. The company's focus on bispecific antibodies and combination therapies aligns with broader industry trends toward more targeted and effective cancer treatments. With a robust pipeline and significant partnerships, Akeso is poised to redefine clinical standards in multiple tumor types and chronic disease areas.
What we're watching
- Regulatory Momentum
- How the FDA's review of ivonescimab for EGFR-TKI-resistant NSCLC will impact Akeso's global expansion.
- Combination Therapy Strategy
- Whether Akeso's IO2.0 + ADC2.0 therapeutic matrix can sustain its pipeline momentum across multiple indications.
- AI-Driven Innovation
- The pace at which Akeso's AI-powered drug discovery platform will advance its frontier programs into clinical development.
Related topics